Correction to: Environ Health Prev Med (2019) 24:80
https://doi.org/10.1186/s12199-019-0837-1
Anzeige
Following publication of the original article [1], the authors spotted an error in their paper concerning the positive rate in the right side in Table 2.
That is, 89.7 not 89., 93.5 not 93., 56.7 not 56., 75.3 not 75. and 94.0 not 94..
The original article has been corrected. The correct presentation of Table 2 is shown below.
Table 2
Positive rate of HBs antibody after HB vaccination
Vaccine Administration route | Total number | Age range, median (IQR) | HBs antibody | Positive rate (%) | Sex | Total number | Age range, median (IQR) | HBs antibody | Positive rate (%) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Median (IQR) | (+) | (−) | (+) | (−) | ||||||||
Bimmugen® subcutaneous | 514 | 19–25, 20 (19–21) | 84.9 (34.5–217) mIU/mL | 473 | 41 | 92.0 * | Men | 204 | 19–25, 20 (19–21) | 183 | 21 | 89.7 † |
Women | 310 | 19–22, 19 (19–19) | 290 | 20 | 93.5 ‡ | |||||||
Heptavax-II® subcutaneous | 373 | 19–30, 20 (19–21) | 28.7 (5–216) mIU/mL | 248 | 125 | 66.3 * | Men | 180 | 19–30, 20 (19–21) | 102 | 72 | 56.7 † |
Women | 193 | 19–22, 19 (19–19) | 146 | 47 | 75.3 ‡ | |||||||
Heptavax-II® intramuscular | 247 | 19–27, 20 (19–21) | 190 (41.6–534) mIU/mL | 220 | 27 | 89.1 * | Men | 97 | 19–27, 20 (19–21) | 79 | 18 | 81.4 † |
Women | 150 | 19–22, 19 (19–20) | 141 | 9 | 94.0 ‡ | |||||||
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.